Champoux Jennifer 4

What Happened
Jennifer Champoux, Chief Operating Officer of Monte Rosa Therapeutics (GLUE), exercised 2,176 stock options at $3.98 per share (cost $8,660) on 2026-06-17 and sold the same 2,176 shares in an open-market transaction at $19.00 per share, receiving $41,344. The transactions net to approximately $32,684 in proceeds before taxes and fees. The Form 4 also lists a related derivative conversion entry for 2,176 shares at $0, which appears to reflect the administrative conversion/settlement of the options.

Key Details

• Transaction date: 2026-06-17; Form filed: 2026-06-18 (timely filing).
• Exercise: 2,176 shares @ $3.98 = $8,660 (acquired).
• Sale: 2,176 shares @ $19.00 = $41,344 (disposed).
• Additional derivative line: 2,176 shares @ $0.00 (disposed) — administrative conversion entry shown on the form.
• Shares owned after transaction: Not specified in the provided filing details.
• Footnotes: F1 — sale effected under a Rule 10b5-1 trading plan adopted Feb 19, 2026; F2 — option vesting schedule (25% vested May 28, 2025; remainder vests monthly over ~36 months subject to continued service).

Context

• This was an exercise of options followed by an immediate sale of the resulting shares (commonly a cashless exercise / same-day sale). That pattern typically converts option value to cash rather than signalling a hold or long-term buy.
• The sale was executed under a pre-established 10b5-1 plan (per F1), which is a preset trading arrangement that can allow insiders to sell shares at scheduled times.
• No indication in the provided details that this was a gift or tax-withholding share surrender beyond the administrative derivative line; do not infer motive from the filing.